A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab
Shigoka, M.; Enomoto, M.; Wada, T.; Mazaki, J.; Kuwabara, H.; Ishizaki, T.; Ishibashi, Y.; Nagakawa, Y.; Katsumata, K.; Tsuchida, A.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(4): 796-798
2019
ISSN/ISBN: 0385-0684 PMID: 31164539 Document Number: 699240
A 60-year-old woman underwent intersphincteric resection for lower rectal cancer in 2016. The pathological stage was pT3N1M0, stage Ⅲa and the cancer was curatively resected. Local recurrence was detected 6 months after the surgery. The patient received chemotherapy of 4 courses of FOLFOXIRI plus bevacizumab(Bev). A Grade 4 adverse event(febrile neutropenia) occurred but the treatment was continued after a dose reduction to 80%. The size of the tumor decreased significantly after chemotherapy and posterior pelvic exenteration with sacral resection was performed. Pathological analysis revealed a positive radial margin but there were no remarkable complications after surgery and no obvious recurrence during the 9 months after the operation. Therefore, we concluded that FOLFOXIRI plus Bev chemotherapy is a manageable and useful treatment for locally recurrent rectal cancer.